Gan to kagaku ryoho. Cancer & chemotherapy
-
Palliative home care supports the quality of life (QOL) of a patient and family as a whole. Team care is an effective method corresponding to the various needs of the patient and family. Cooperation of various types of professions can meet the need for high-quality outpatient medical care. ⋯ Therefore, spirituality issues are important. Palliative home care must respect and understand the spirituality of the patient and family. The patient can be discharged from the hospital in peace when there is general support for the physical, psycho-social and spiritual needs of both patient and family.
-
Gan To Kagaku Ryoho · Oct 2010
Historical Article[Introduction to palliative care for the oncologist-history and basic principles of palliative care].
The basic principle of palliative care has evolved over time and is the historical origin of the modern hospice. WHO proposed the first definition of palliative care in 1989, and the definition was revised in 2002. These definitions have something in common. ⋯ Specialist palliative care is based on the basic principles of palliative care, intensive clinical training, and systematic acquisition of knowledge and skills training to support palliative care education, clinical research and training provided by the profession. It has been established by nursing and medical experts in palliative care that palliative care can provide expertise in interdisciplinary teams in different settings. It is necessary that the medical system.
-
Gan To Kagaku Ryoho · Sep 2010
[A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch].
We examined the efficacy and safety of a new transdermal fentanyl citrate patch (HFT-290), which was applied once daily in patients with cancer pain who were receiving a stable dose of once-every-three-day application transdermal fentanyl patch [TDF (72 hr)]. After TDF (72 hr) was applied for three days at the same dose used before starting the study, treatment was switched to HFT-290 (once daily) for 9 days. The analgesic effect was judged with a 5-point scale based on each patient's assessment of pain on a 100-mm visual analog scale (VAS). ⋯ All adverse drug reactions were either mild or moderate, and the main reactions were those commonly observed with opioid analgesics. No respiratory depression was observed. HFT-290 demonstrated good tolerability after switching from TDF (72 hr) and provided stable pain control.
-
Gan To Kagaku Ryoho · Aug 2010
[The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Japanese patients with bone metastases--The Japanese version of the EORTC QLQ-BM22].
Bone metastasis is a frequent complication of malignant cancer. Previous clinical trials of bone metastasis have largely focused on skeletal related events (SREs) as objective end-points. ⋯ In this study, we introduce the official Japanese version of the EORTC QLQ-BM22 as a module to evaluate QOL in patients with bone metastasis. This module has been developed to be used together with the EORTC QLQ-C30, a QOL scale for patients with cancer, or with its shortened version, EORTC QLQ-C-15-PAL.
-
Gan To Kagaku Ryoho · Jul 2010
Case Reports[A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy].
We experienced a case of anthracycline- and taxane-resistant recurrent breast cancer with multiple liver metastases and multiple bone metastases showing marked improvement by S-1. A 52-year-old woman visited our hospital because of her liver dysfunction in May 2008. She underwent a partial mastectomy preserving chest muscles in another hospital in 2000, but further details were unknown. ⋯ Then the oral treatment with S-1 was started, and at the end of the second course, a significant reduction of abnormal accumulation in PET was noted. She has been quite well without any adverse effects from S-1. S-1 monotherapy was thus considered to be an effective treatment for advanced or recurrent breast cancer resistant to anthracyclines and taxanes.